Literature DB >> 9025700

Seroepidemiology of Entamoeba histolytica in a slum in northeastern Brazil.

L L Braga1, A A Lima, C L Sears, R D Newman, T Wuhib, C A Paiva, R L Guerrant, B J Mann.   

Abstract

Infection with the human pathogenic parasite Entamoeba histolytica has not been well-characterized in northeastern Brazil. In this study, the prevalence of E. histolytica infection in a slum in northeastern Brazil was assayed using an enzyme-linked immunosorbent assay (ELISA) for antibodies against the galactose/N-acetyl-D-galactosamine (Gal/GalNAc)-inhibitable adherence lectin of E. histolytica. Sera from a total of 335 individuals were examined for anti-Gal/GalNAc lectin antibodies. The overall seropositivity was 24.7%; 29.4% of females and 19.4% of males were positive. Among different age groups there was a peak of 40% positivity in the 6-14-year-old age group. There was also familial clustering of seropositivity. To examine colonization, stool samples from 155 people were examined microscopically for the presence of the parasite. Fourteen of 155 stools (9.0%) were identified as containing E. histolytica or nonpathogenic E. dispar. These 14 positive stools were analyzed with an ELISA that detects Gal/GalNAc lectin antigen and can distinguish between E. histolytica and E. dispar. Four stools (29%) were positive for E. histolytica and the remaining 10 were identified as E. dispar-positive. Although the overall colonization rate by microscopy was only 9%, with a third identified as E. histolytica, up to 40% of older children develop serologic evidence of having experienced pathogenic E. histolytica infection. The results of this study demonstrate that this community in northeastern Brazil is highly endemic for E. histolytica with infection rates similar to other developing nations.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9025700     DOI: 10.4269/ajtmh.1996.55.693

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  11 in total

Review 1.  Vaccines to combat the neglected tropical diseases.

Authors:  Jeffrey M Bethony; Rhea N Cole; Xiaoti Guo; Shaden Kamhawi; Marshall W Lightowlers; Alex Loukas; William Petri; Steven Reed; Jesus G Valenzuela; Peter J Hotez
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

2.  Prevalence of Intestinal Parasites among Patients of Al-Noor Specialist Hospital, Makkah, Saudi Arabia.

Authors:  Dina Am Zaglool; Yousif Aw Khodari; Zohair J Gazzaz; Khalid O Dhafar; Hani As Shaker; Mian U Farooq
Journal:  Oman Med J       Date:  2011-05

3.  Seropositivity for and intestinal colonization with Entamoeba histolytica and entamoeba dispar in individuals in northeastern Brazil.

Authors:  L L Braga; Y Mendonca; C A Paiva; A Sales; A L Cavalcante; B J Mann
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

4.  Expression, purification, and evaluation of recombinant LecA as a candidate for an amebic colitis vaccine.

Authors:  L Barroso; M Abhyankar; Z Noor; K Read; K Pedersen; R White; C Fox; W A Petri; D Lyerly
Journal:  Vaccine       Date:  2013-07-01       Impact factor: 3.641

Review 5.  Pathogenesis of intestinal amebiasis: from molecules to disease.

Authors:  M Espinosa-Cantellano; A Martínez-Palomo
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

6.  Real-time-PCR assay for diagnosis of Entamoeba histolytica infection.

Authors:  Shantanu Roy; Mamun Kabir; Dinesh Mondal; Ibne Karim M Ali; William A Petri; Rashidul Haque
Journal:  J Clin Microbiol       Date:  2005-05       Impact factor: 5.948

Review 7.  Laboratory diagnosis of amebiasis.

Authors:  Mehmet Tanyuksel; William A Petri
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

Review 8.  Host-pathogen interaction in amebiasis and progress in vaccine development.

Authors:  C D Huston; W A Petri
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-09       Impact factor: 3.267

9.  Amebiasis: Clinical Implications of the Recognition of Entamoeba dispar.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-12       Impact factor: 3.663

10.  Antiamoebic drugs for treating amoebic colitis.

Authors:  Maria Liza M Gonzales; Leonila F Dans; Juliet Sio-Aguilar
Journal:  Cochrane Database Syst Rev       Date:  2019-01-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.